Media headlines about Johnson & Johnson (NASDAQ:JNJ
) have trended somewhat positive recently, according to Accern Sentiment Analysis. The research group identifies positive and negative news coverage by monitoring more than twenty million news and blog sources in real-time. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Johnson & Johnson earned a daily sentiment score of 0.18 on Accern’s scale. Accern also assigned news coverage about the company an impact score of 46.5118257347334 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.
Johnson & Johnson (JNJ
) traded down 0.31% during mid-day trading on Friday, hitting $132.63. 4,792,761 shares of the company were exchanged. Johnson & Johnson has a 12-month low of $109.32 and a 12-month high of $137.08. The company’s 50-day moving average is $132.88 and its 200 day moving average is $127.04. The company has a market capitalization of $355.98 billion and a P/E ratio of 22.44.
COPYRIGHT VIOLATION WARNING: This report was originally published by Community Financial News and is the property of of Community Financial News. If you are accessing this report on another website, it was copied illegally and republished in violation of U.S. and international copyright and trademark law. The original version of this report can be accessed at https://www.com-unik.info/2017/08/19/johnson-johnson-jnj-earns-media-sentiment-rating-of-0-18-updated-updated-updated.html.
Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.
What are top analysts saying about Johnson & Johnson? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Johnson & Johnson and related companies.